TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre, Multinational, Double-Blind, Placebo-Controlled, Randomised Phase II Trial of Desmoteplase (INN) in the Indication of Acute Ischaemic Stroke
Brief Summary: The DIAS study (Part 2) was performed to support the dose finding of desmoteplase treatment in subjects with acute ischemic stroke selected by perfusion/diffusion mismatch on MRI within a time window of 3 to 9 h after stroke-symptom onset. In addition, it assessed safety and tolerability of 3 doses of desmoteplase compared with placebo with special consideration of intracranial hemorrhage and major systemic bleedings.


Options:
A: Intervention Type: DRUG; Name: rt-PA 0.9 mg/kg verum or placebo Intravenous; Assigned to Arm(s): N/A
B: Arm Label: Desmoteplase, low dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Desmoteplase, high dose; Type: EXPERIMENTAL; Interventions: Drug: Desmoteplase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, low dose | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): Desmoteplase, high dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desmoteplase | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Desmoteplase; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Clinical Trial With Memantine for Cognitive Deficits in Patients With Multiple Sclerosis
Brief Summary: To assess the efficacy of Memantine in improving the cognitive impairment in patients with Multiple Sclerosis (MS)


Options:
A: Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol, Drug: Memantine | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 4
C: Arm Label: 1; Type: N/A; Interventions: Procedure: Magnetic Resonance Imaging (MRI), Procedure: Positron Emission Tomography (PET), Procedure: Lumbar Puncture (LP) | Arm Label: 2; Type: N/A; Interventions: Procedure: Magnetic Resonance Imaging (MRI), Procedure: Positron Emission Tomography (PET), Procedure: Lumbar Puncture (LP) | Arm Label: 3; Type: N/A; Interventions: Procedure: Magnetic Resonance Imaging (MRI), Procedure: Positron Emission Tomography (PET), Procedure: Lumbar Puncture (LP) | Intervention Type: PROCEDURE; Name: Magnetic Resonance Imaging (MRI); Assigned to Arm(s): 1, 2, 3 | Intervention Type: PROCEDURE; Name: Positron Emission Tomography (PET); Assigned to Arm(s): 1, 2, 3 | Intervention Type: PROCEDURE; Name: Lumbar Puncture (LP); Assigned to Arm(s): 1, 2, 3
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phenylephrine Versus Norepinephrine in Septic Shock: Effects on Systemic and Regional Hemodynamics. A Randomized, Controlled, Trial
Brief Summary: The present study was conducted as a prospective, randomized, controlled study to compare:

* the effects of norepinephrine and phenylephrine on systemic and regional hemodynamics in patients with catecholamine-dependent septic shock
* to test the hypothesis that norepinephrine may likewise better preserve hepatosplanchnic perfusion versus phenylephrine in patients suffering from septic shock


Options:
A: Arm Label: high pressure; Type: ACTIVE_COMPARATOR; Interventions: Drug: maintain mean arterial pressure between 80-85 mm Hg | Arm Label: normal pressure; Type: PLACEBO_COMPARATOR; Interventions: Other: maintain mean arterial pressure between 65-70 mm Hg | Intervention Type: DRUG; Name: maintain mean arterial pressure between 80-85 mm Hg; Assigned to Arm(s): high pressure | Intervention Type: OTHER; Name: maintain mean arterial pressure between 65-70 mm Hg; Assigned to Arm(s): normal pressure
B: Arm Label: continuous terlipressin; Type: EXPERIMENTAL; Interventions: Drug: continuous infusion of terlipressin | Arm Label: vasopressin; Type: EXPERIMENTAL; Interventions: Drug: Arginine vasopressin | Arm Label: terlipressin bolus dose; Type: EXPERIMENTAL; Interventions: Drug: terlipressin bolus administration | Intervention Type: DRUG; Name: continuous infusion of terlipressin; Assigned to Arm(s): continuous terlipressin | Intervention Type: DRUG; Name: Arginine vasopressin; Assigned to Arm(s): vasopressin | Intervention Type: DRUG; Name: terlipressin bolus administration; Assigned to Arm(s): terlipressin bolus dose
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Phenylephrine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Norepinephrine | Intervention Type: DRUG; Name: Phenylephrine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Norepinephrine; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: norepinephrine and dobutamine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: epinephrine plus placebo of dobutamine | Intervention Type: DRUG; Name: norepinephrine and dobutamine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: epinephrine plus placebo of dobutamine; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BREAST CANCER AND EXERCISE BREX: A Multicenter Phase III Open Randomised Trial of the Efficacy of Exercise in the Prevention of Long-term Adverse Effects of Adjuvant Treatments and Breast Cancer Recurrences in Women With Primary Breast Cancer.
Brief Summary: A Finnish Breast Cancer Group Study (BREX 01-2004). A multicenter phase III open randomised trial of the efficacy of exercise in the prevention of long-term adverse effects of adjuvant treatments and breast cancer recurrences in women with primary breast cancer. The aim of the study is to investigate whether regular exercise training could reduce the long-term side effects of adjuvant treatments of primary breast cancer and improve quality of life and well being.


Options:
A: Arm Label: Non-Exercise Control Group; Type: N/A; Interventions: Behavioral: Exercise | Arm Label: 4-kcal/kg Energy Expenditure per week; Type: N/A; Interventions: Behavioral: Exercise | Arm Label: 8-kcal/kg Energy Expenditure per week; Type: N/A; Interventions: Behavioral: Exercise | Arm Label: 12-kcal/kg Energy Expenditure per week; Type: N/A; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 12-kcal/kg Energy Expenditure per week, 4-kcal/kg Energy Expenditure per week, 8-kcal/kg Energy Expenditure per week, Non-Exercise Control Group
B: Arm Label: A; Type: OTHER; Interventions: Other: supervised training | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: supervised training; Assigned to Arm(s): A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Low impact exercise | Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low impact exercise; Assigned to Arm(s): 2
D: Arm Label: 1; Type: OTHER; Interventions: Behavioral: Regular aerobic physical exercise | Arm Label: 2; Type: OTHER; Interventions: Dietary Supplement: Micronutrients | Arm Label: 3; Type: OTHER; Interventions: Behavioral: Regular aerobic physical exercise, Dietary Supplement: Micronutrients | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Other: Activities of daily living + placebo | Intervention Type: BEHAVIORAL; Name: Regular aerobic physical exercise; Assigned to Arm(s): 1, 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrients; Assigned to Arm(s): 2, 3 | Intervention Type: OTHER; Name: Activities of daily living + placebo; Assigned to Arm(s): 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase II/III Trial of Second Line Chemotherapy Comparing CPT-11 Monotherapy Versus S-1/CPT-11 Combination for S-1 Refractory Gastric Cancer
Brief Summary: The purpose of this study is compare overall survival of the test arm (CPT-11/S-1 combination) to the control arm (CPT-11 alone) in the subjects with S-1 refractory advanced gastric cancer.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: S-1 + irinotecan | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: irinotecan | Intervention Type: DRUG; Name: S-1 + irinotecan; Assigned to Arm(s): A | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): B
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: 5-Fluorouracil, Drug: Oxaliplatin, Drug: folinic acid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fluorouracil, Drug: Oxaliplatin, Drug: folinic acid | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: folinic acid; Assigned to Arm(s): 1, 2
C: Arm Label: Standard taxane therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Taxane | Arm Label: trastuzumab emtansine 2.4 mg; Type: EXPERIMENTAL; Interventions: Drug: trastuzumab emtansine | Arm Label: trastuzumab emtansine 3.6 mg; Type: EXPERIMENTAL; Interventions: Drug: trastuzumab emtansine | Intervention Type: DRUG; Name: Taxane; Assigned to Arm(s): Standard taxane therapy | Intervention Type: DRUG; Name: trastuzumab emtansine; Assigned to Arm(s): trastuzumab emtansine 3.6 mg | Intervention Type: DRUG; Name: trastuzumab emtansine; Assigned to Arm(s): trastuzumab emtansine 2.4 mg
D: Arm Label: Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Trial Evaluating Efficacy and Safety of Single i.v. Bolus Tenecteplase Plus Standard Anticoagulation as Compared With Standard Anticoagulation in Normotensive Patients
Brief Summary: Heparin is the reference therapy for most patients with pulmonary embolism. Some patients with sub-massive pulmonary embolism defined by normal blood pressure and dysfunction of the right ventricle have a higher mortality risk. It has been suggested that thrombolytic treatment, a drug that dissolves blood clots more rapidly, may reduce the mortality in those patients. The studies reported to date were unable to confirm or refute this hypothesis because the number of patients included in those studies is too low. The aim of the study is to compare thrombolytic treatment with heparin (which is the reference therapy for pulmonary embolism) in a large group of patients with sub-massive pulmonary embolism.


Options:
A: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention
B: Arm Label: group A; Type: EXPERIMENTAL; Interventions: Drug: tenecteplase (group A) | Arm Label: group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo ( group B) | Intervention Type: DRUG; Name: placebo ( group B); Assigned to Arm(s): group B | Intervention Type: DRUG; Name: tenecteplase (group A); Assigned to Arm(s): group A
C: Intervention Type: DRUG; Name: tenecteplase; Assigned to Arm(s): N/A
D: Arm Label: Ultrasound accelerated thrombolysis; Type: EXPERIMENTAL; Interventions: Device: EkoSonic Endovascular System | Arm Label: Intravenous unfractionated heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Intervention Type: DEVICE; Name: EkoSonic Endovascular System; Assigned to Arm(s): Ultrasound accelerated thrombolysis | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Intravenous unfractionated heparin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Trial Evaluating Efficacy and Safety of Single i.v. Bolus Tenecteplase Plus Standard Anticoagulation as Compared With Standard Anticoagulation in Normotensive Patients
Brief Summary: Heparin is the reference therapy for most patients with pulmonary embolism. Some patients with sub-massive pulmonary embolism defined by normal blood pressure and dysfunction of the right ventricle have a higher mortality risk. It has been suggested that thrombolytic treatment, a drug that dissolves blood clots more rapidly, may reduce the mortality in those patients. The studies reported to date were unable to confirm or refute this hypothesis because the number of patients included in those studies is too low. The aim of the study is to compare thrombolytic treatment with heparin (which is the reference therapy for pulmonary embolism) in a large group of patients with sub-massive pulmonary embolism.


Options:
A: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline + Enoxaparin | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tenecteplase + Enoxaparin | Intervention Type: DRUG; Name: Tenecteplase + Enoxaparin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 0.9% Saline + Enoxaparin; Assigned to Arm(s): 2
B: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Urokinase | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: Urokinase | Intervention Type: DRUG; Name: Urokinase; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Urokinase; Assigned to Arm(s): Group 2
C: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: rt-PA | Arm Label: group 2; Type: EXPERIMENTAL; Interventions: Drug: rt-PA | Intervention Type: DRUG; Name: rt-PA; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: rt-PA; Assigned to Arm(s): group 2
D: Arm Label: group A; Type: EXPERIMENTAL; Interventions: Drug: tenecteplase (group A) | Arm Label: group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo ( group B) | Intervention Type: DRUG; Name: placebo ( group B); Assigned to Arm(s): group B | Intervention Type: DRUG; Name: tenecteplase (group A); Assigned to Arm(s): group A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Trial Evaluating Efficacy and Safety of Single i.v. Bolus Tenecteplase Plus Standard Anticoagulation as Compared With Standard Anticoagulation in Normotensive Patients
Brief Summary: Heparin is the reference therapy for most patients with pulmonary embolism. Some patients with sub-massive pulmonary embolism defined by normal blood pressure and dysfunction of the right ventricle have a higher mortality risk. It has been suggested that thrombolytic treatment, a drug that dissolves blood clots more rapidly, may reduce the mortality in those patients. The studies reported to date were unable to confirm or refute this hypothesis because the number of patients included in those studies is too low. The aim of the study is to compare thrombolytic treatment with heparin (which is the reference therapy for pulmonary embolism) in a large group of patients with sub-massive pulmonary embolism.


Options:
A: Arm Label: pulmonary embolism; Type: N/A; Interventions: N/A
B: Arm Label: group A; Type: EXPERIMENTAL; Interventions: Drug: tenecteplase (group A) | Arm Label: group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo ( group B) | Intervention Type: DRUG; Name: placebo ( group B); Assigned to Arm(s): group B | Intervention Type: DRUG; Name: tenecteplase (group A); Assigned to Arm(s): group A
C: Arm Label: Patients undergoing Pulmonary Embolectomy; Type: N/A; Interventions: Procedure: Catheter directed debulking of Pulmonary Embolus | Intervention Type: PROCEDURE; Name: Catheter directed debulking of Pulmonary Embolus; Assigned to Arm(s): Patients undergoing Pulmonary Embolectomy
D: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical and Histological Evaluation of OSSIX-Plus Resorbable Collagen Membranes for Alveolar Ridge Preservation Following Exodontia
Brief Summary: The purpose of this study is to evaluate clinically, histologically and radiographically the healing of extraction sockets covered with a resorbable collagen membrane (OSSIX-Plus) 12 weeks following exodontia.


Options:
A: Arm Label: Combination 50% cortical/50% cancellous FDBA; Type: EXPERIMENTAL; Interventions: Device: 50% cortical/50% cancellous FDBA | Arm Label: 100% cortical FDBA; Type: ACTIVE_COMPARATOR; Interventions: Device: 100% cortical FDBA | Arm Label: 100% cancellous FDBA; Type: ACTIVE_COMPARATOR; Interventions: Device: 100% cancellous FDBA | Intervention Type: DEVICE; Name: 50% cortical/50% cancellous FDBA; Assigned to Arm(s): Combination 50% cortical/50% cancellous FDBA | Intervention Type: DEVICE; Name: 100% cortical FDBA; Assigned to Arm(s): 100% cortical FDBA | Intervention Type: DEVICE; Name: 100% cancellous FDBA; Assigned to Arm(s): 100% cancellous FDBA
B: Arm Label: Placing OSSIX-Plus in Extraction Site; Type: EXPERIMENTAL; Interventions: Device: OSSIX-Plus | Intervention Type: DEVICE; Name: OSSIX-Plus; Assigned to Arm(s): Placing OSSIX-Plus in Extraction Site
C: Arm Label: cancellous FDBA (LifeNet); Type: EXPERIMENTAL; Interventions: Device: Cancellous FDBA | Arm Label: cortical FDBA (LifeNet); Type: EXPERIMENTAL; Interventions: Device: cortical FDBA | Intervention Type: DEVICE; Name: cortical FDBA; Assigned to Arm(s): cortical FDBA (LifeNet) | Intervention Type: DEVICE; Name: Cancellous FDBA; Assigned to Arm(s): cancellous FDBA (LifeNet)
D: Arm Label: Test: Porcine Xenograft (Zcore); Type: EXPERIMENTAL; Interventions: Device: Porcine Xenograft (Zcore) | Arm Label: Active Control: Bovine Xenograft (Bio-Oss); Type: ACTIVE_COMPARATOR; Interventions: Device: Bovine Xenograft (Bio-Oss) | Intervention Type: DEVICE; Name: Porcine Xenograft (Zcore); Assigned to Arm(s): Test: Porcine Xenograft (Zcore) | Intervention Type: DEVICE; Name: Bovine Xenograft (Bio-Oss); Assigned to Arm(s): Active Control: Bovine Xenograft (Bio-Oss)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Clinical Trial of the Standard Two Dose Nevirapine (NVP) Regimen With the Addition of HIV Immune Globulin(HIVIGLOB) or Extended Infant NVP Dosing Compared With the Standard NVP Regimen Alone for the Prevention of Maternal-Infant HIV Transmission in Uganda
Brief Summary: The increase in pediatric HIV infection has a substantial impact on childhood mortality in the developing world. A number of recent studies suggest that as many as half or more of mother-to-child HIV transmissions in developing countries occur in late pregnancy or during labor and delivery. Interventions targeted during the perinatal period have shown to be effective and to have a significant impact in reducing transmission. The purpose of this study is to investigate the effectiveness of nevirapine (NVP) plus immunoprophylaxis or extended NVP dosing regimens in HIV-infected pregnant women and their infants during the perinatal period.


Options:
A: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Combined short-course zidovudine/nevirapine | Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: HAART | Intervention Type: DRUG; Name: Combined short-course zidovudine/nevirapine; Assigned to Arm(s): B | Intervention Type: DRUG; Name: HAART; Assigned to Arm(s): A
B: Arm Label: maternal nevirapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: maternal placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: No intervention | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): maternal nevirapine | Intervention Type: DRUG; Name: No intervention; Assigned to Arm(s): maternal placebo
C: Arm Label: Trizivir (TZV) Arm; Type: EXPERIMENTAL; Interventions: Drug: Trizivir | Arm Label: Kaletra Arm; Type: EXPERIMENTAL; Interventions: Drug: Lamivudine/Zidovudine, Drug: Lopinavir/Ritonavir | Arm Label: Nevirapine (NVP) Arm; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Intervention Type: DRUG; Name: Trizivir; Assigned to Arm(s): Trizivir (TZV) Arm | Intervention Type: DRUG; Name: Lamivudine/Zidovudine; Assigned to Arm(s): Kaletra Arm | Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): Kaletra Arm | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): Nevirapine (NVP) Arm
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine, Drug: HIV immune globulin solution | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: HIV immune globulin solution; Assigned to Arm(s): 3

Answer: D